No results for ‘’
Jubilant Pharmova Ltd
₹1023.85
(0.12%)
Tue, 28 Jul 2026, 03:35 am
Health Technology
Pharmaceuticals: Major
24.5KJubilant Pharmova Enterprise Value (EV)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 28.49 | 20 | 14.49 | 5.76 | 13.71 | 12.65 | 219.45 | 17.70 | 23.20 | 0 | 16.60 | 21.63 | 20.36 | 18.02 | 4.41 | 12.96 | 14.91 | 0 | 117.13 | 16.90 |
| Price to book ratio | 4.21 | 4.12 | 3.78 | 1.11 | 2.45 | 1.21 | 1.41 | 1.08 | 0.96 | 0.99 | 2.24 | 3.62 | 3.20 | 2.20 | 0.71 | 2.28 | 1.16 | 0.82 | 1.66 | 2.26 |
| Price to sales ratio | 2.52 | 2.52 | 2.33 | 0.46 | 1.53 | 0.85 | 0.75 | 0.53 | 0.44 | 0.42 | 1.14 | 2.15 | 1.76 | 1.15 | 0.66 | 1.78 | 1.01 | 0.71 | 1.35 | 1.96 |
| Price to cash flow ratio | 243.70 | 23.59 | 22.34 | 3.52 | 10.26 | 10.37 | 6.18 | 3.62 | 5.35 | 5.34 | 8.66 | 11.94 | 11.96 | 11.32 | 3.19 | 7.24 | 8.74 | 10.18 | 11.99 | 16.21 |
| Enterprise value | 4314Cr | 5359Cr | 7409Cr | 5160Cr | 8486Cr | 5826Cr | 6802Cr | 6251Cr | 6605Cr | 6827Cr | 10615Cr | 15991Cr | 16256Cr | 13823Cr | 7372Cr | 12995Cr | 8378Cr | 7096Cr | 11725Cr | 15808Cr |
| Enterprise value to EBITDA ratio | 19.94 | 20.47 | 16.01 | 7.65 | 12.75 | 10.61 | 8.14 | 5.98 | 7.02 | 10.46 | 8.40 | 12.37 | 11.18 | 8.09 | 4.64 | 8.91 | 6.94 | 9.33 | 13.08 | 15.17 |
| Debt to equity ratio | 0.88 | 1.82 | 1.68 | 3.06 | 1.45 | 1.81 | 1.69 | 1.52 | 1.67 | 1.95 | 1.51 | 1.18 | 0.85 | 1.01 | 0.86 | 0.60 | 0.60 | 0.68 | 0.67 | 0.44 |
| Return on equity % | 19.50 | 26.33 | 37.04 | 22.44 | 24.38 | 10.53 | 0.66 | 6.43 | 4.26 | -2.27 | 14.46 | 17.98 | 17.09 | 12.92 | 13.02 | 11.10 | 8.23 | -1.14 | 1.42 | 14.36 |
Jubilant Pharmova Ltd Enterprise Value
The Jubilant Pharmova Ltd Enterprise Value is a key financial metric used by investors to evaluate Jubilant Pharmova Ltd's valuation, profitability, and overall financial performance. Tracking the Jubilant Pharmova Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Jubilant Pharmova Ltd (NSE: JUBLPHARMA, BSE: 530019) is currently trading at ₹1023.85, with a market capitalization of ₹16282.51Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Jubilant Pharmova Ltd Enterprise Value is essential for fundamental analysis.
Jubilant Pharmova Ltd Enterprise Value Current Value
The current Jubilant Pharmova Ltd Enterprise Value stands at 15808Cr.
The latest Jubilant Pharmova Ltd Enterprise Value has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Jubilant Pharmova Ltd Enterprise Value Historical Trend
The Jubilant Pharmova Ltd Enterprise Value has shown the following historical trend:
- 2024: 15808Cr
- 2023: 11725Cr
- 2022: 7096Cr
- 2021: 8378Cr
- 2020: 12995Cr
The recent rise in Jubilant Pharmova Ltd Enterprise Value suggests strengthening valuation trends and improving market sentiment.
What Jubilant Pharmova Ltd Enterprise Value Indicates for Investors
The Jubilant Pharmova Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Jubilant Pharmova Ltd.
Jubilant Pharmova Ltd Enterprise Value Analysis Summary
The Jubilant Pharmova Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Jubilant Pharmova Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Jubilant Pharmova Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.